|
1 pahu (10 Vials)
| Ka nui: | |
|---|---|
▎ ARA-290 Hoʻolālā
Puna: PubChem |
Kakau: XEQLERALNSS Hui Molekala: C 51H 84N 16O21 Kaumaha Molekala: 1257.3g/mol Helu CAS:1208243-50-8 PubChem CID:91810664 Synonyms: Cibinetide |
▎ ARA-290 ʻImi
He aha ke kumu noiʻi o ARA-290?
Hoʻokumu ʻia ka hoʻomohala ʻana o ARA-290 mai ka ʻimi ʻana i ka hiki ke hoʻōla o ka erythropoietin (EPO). Ua ʻike nā kānaka ʻepekema ʻaʻole hoʻolaha wale ʻo EPO i ka erythropoiesis akā loaʻa pū kekahi mau hana pale kino e like me ka anti-inflammation a me ka anti-apoptosis. Eia nō naʻe, hiki i ka hoʻoulu ʻana o ka hematopoietic EPO ke hoʻonui i ka viscosity koko a me nā pilikia ʻē aʻe, e kaupalena ana i kona hoʻohana ʻana i ka mālama ʻana i nā maʻi non-anemia. No ka hoʻopaʻa ʻana i nā hopena pale kino o ka EPO me ka pale ʻana i nā hopena ʻaoʻao hematopoietic, ua hoʻomaka nā mea noiʻi e hoʻolālā i nā peptides derivative, e alakaʻi ana i ka hana ʻana o ARA-290.
Me ka noiʻi hohonu, ʻike ʻia nā pono kūʻokoʻa o ARA-290 ma ke ʻano he peptide non-hematopoietic. Hoʻoulu ia i nā ala hōʻailona anti-inflammatory a me ka hoʻoponopono ʻana i ka ʻiʻo ma o ka hoʻopaʻa ʻana i ka innate repair receptor (IRR), e hōʻike ana i nā hopena hoʻohiki i ka mālama ʻana i nā hoʻopiʻi maʻi diabetic, neuropathies, a me nā ʻeha renal. Ua hoʻokumu kēia mau ʻike i ke kumu no ka noiʻi hou aʻe a me nā noi lapaʻau o ARA-290 a hāpai i ka hoʻomohala ʻana i nā hoʻolālā therapeutic novel e pili ana i nā peptides i loaʻa i ka EPO.
He aha ke ʻano o ka hana o ARA-290?
ʻO ka hopena Anti-Inflammatory: ARA-290 ke kāohi i ka huna ʻana o nā cytokines inflammatory, a laila e hōʻemi i nā pane inflammatory, e like me ka hōʻike ʻana i nā ʻano maʻi he nui. No ka laʻana, i loko o kahi kiʻi ʻiole o systemic lupus erythematosus (SLE), e hōʻemi ana i ka serum concentrations o nā cytokine inflammatory IL-6, MCP-1, a me TNF-α, e hoʻomaikaʻi ana i nā hōʻailona SLE {#Dahan, A,2016} (Dahan A, 2016). I loko o ka cisplatin-induced nephrotoxicity model, hoʻemi ia i nā cytokine pro-inflammatory TNFα, IL6, a me IL1β, e hoʻopau ana i ka ʻeha renal [2] (Ghassemi-Barghi N, 2023). Hiki i kāna hana anti-inflammatory ke komo i ka huli ʻana i ka innate repair receptor (IRR), he heterodimer o ka erythropoietin receptor a me β-common (CD131) receptor. ʻO ka hoʻopaʻa ʻana i ka IRR e hoʻāla i nā ala hōʻailona anti-inflammatory downstream, a laila e hoʻohaʻahaʻa i ka mumū [1].
ʻAi-Apoptotic Effect: ARA-290 inhibits cell apoptosis and promoted tissue cell survival. I loko o kahi ʻano ʻiole diabetic, hoʻopau ia i ka apoptosis cell epithelial tubular renal a hoʻemi i ka hōʻike ʻana o nā proteases kī i ke kaʻina apoptotic, a laila e hoʻokō ai i nā hopena pale. I loko o nā hiʻohiʻona nephrotoxicity i hoʻokomo ʻia e cisplatin, hoʻoponopono ia i ka hōʻike ʻana o nā protein pili i ka apoptosis e like me Bax a me Bcl-2, kaohi ʻana i ka hana Caspase-3, hoʻemi i ka apoptosis cell, a hoʻēmi i ka hōʻino ʻana o ka cisplatin-induced renal cell [2].
Hoʻopiʻi Anti-Oxidative: ARA-290 ke kāohi i ka pōʻino koʻikoʻi oxidative a hoʻemi i ka hana ʻana o nā mea ʻino e like me ka reactive oxygen species (ROS). I loko o ke kŘkohu kŘkohu iole ma'i diabetic, ho'opau ia i ka hō'ike gene renal, ho'emi i ka nui o ka ROS renal, a ho'emi i ka'ōlelo malondialdehyde (MDA), e ho'ēmi ana i ka pō'ino o ka renal i ho'okomo 'ia. Ma nā haʻawina atherosclerosis, hōʻike ʻia nā hoʻokolohua in vitro e kāohi ana ka ARA-290 i ka hana ʻana o ROS i nā macrophages ma lalo o nā kūlana inflammatory, e hōʻemi ana i ka pōʻino oxidative stress i nā cell.
Hoʻoponopono i ka hana o ka Immune Cell Function: Hoʻoponopono ʻo ARA-290 i ka hana o nā cell immune e like me macrophages. In vitro, ke kāohi nei i ka hoʻoulu ʻana o nā macrophages i ka wā e hoʻolaha ana i kā lākou hana phagocytic e pili ana i nā cell apoptotic, e kōkua ana i ka mālama ʻana i ka homeostasis ʻōnaehana immune a me nā cell apoptotic e pale aku i ka mumū ma muli o kā lākou hōʻiliʻili (Dahan A, 2016). I ka noiʻi ʻana i ka atherosclerosis, ua kāohi ʻo ARA-290 i ka neʻe ʻana o ka macrophage a me ka hoʻokumu ʻana o nā cell foam, e hōʻemi ana i ka waiho ʻana o ka lipid i ka intima vascular a me ka hoʻolōʻihi i ka holomua atherosclerosis.
Neuroprotective Mechanism: Ma kahi kiʻi kiʻi o ka cerebral ischemia, ARA-290 hoʻohana i nā hopena neuroprotective ma o ka β-common receptor (βCR). Hoʻemi nui ia i ka apoptosis neuronal a me nā pae cytokine inflammatory i loko o ka lolo lolo, hoʻomaikaʻi i ka hana neurological. ʻO ka hoʻokomo ʻana o ka siRNA i hoʻopaʻa ʻia e βCR ka mea nui e kāohi i nā hopena neuroprotective o ARA-290, e hōʻike ana he hana nui ka βCR i kāna hana [3].
Analgesic Mechanism: Hiki i ka ARA-290 ke hana i nā hopena analgesic ma o ka huli pono ʻana i nā nociceptors peripheral. Hōʻike nā haʻawina i ke kāohi pono ʻana i ka hana channel TRPV1 a hoʻohaʻahaʻa i ka capsaicin-induced mechanical allodynia, e manaʻo ana ʻo ARA-290 hiki ke lawelawe ma ke ʻano he antagonist channel TRPV1 hou, e hāʻawi ana i nā ʻike hou no ka mālama ʻana i ka ʻeha [4].
He aha nā mea hoʻohana o ARA-290?
Lapaʻau ʻana i nā Neuropathies
Pain Relief a me Symptom Improvement: ARA-290 hoʻomaha maikaʻi i ka ʻeha neuropathic, ʻoi loa i nā maʻi me ka neuropathy e like me ka maʻi diabetes a me ka sarcoidosis. I loko o nā hoʻokolohua hoʻokolohua no nā maʻi sarcoidosis, ua hoʻomaikaʻi maikaʻi ʻo ARA-290 i ka neuropathy a me nā hōʻailona nerve autonomic, hoʻonui i ka maikaʻi o ke ola, a hoʻemi i nā helu ʻeha, me nā hopena like i nā maʻi neuropathy diabetic. ʻO kāna hana e pili ana i ka hoʻopaʻa ʻana i ka innate repair receptor (IRR), ka hoʻoulu ʻana i nā ala anti-inflammatory a me ka hoʻoponopono ʻana i ke kino, ka hoʻoponopono ʻana i ka ʻeha neurogenic, a me ka hoʻēmi ʻana i ka ʻeha [1, 4].
Hoʻolaha ʻia o ka Nerve Fiber Regeneration: ARA-290 hoʻoikaika i ka hoʻōla hou ʻana o ke aʻalolo. I nā maʻi maʻi sarcoidosis, 28 mau lā o ka ARA-290 mālama i hoʻoulu i ka corneal liʻiliʻi nerve fiber regeneration, e hōʻike ana i ka hiki ke hoʻoponopono no nā aʻalolo kikoʻī a me ka hiki ke hoʻomaikaʻi i ka hana neurological, ʻoiai ʻaʻohe hopena i nā nerve nerve epidermal [1].
Hoemi i ka Nephrotoxicity
Hoʻemi ʻia ka Cytotoxicity a me Genotoxicity: Ma nā ʻano nephrotoxicity i hoʻokomo ʻia e cisplatin, hoʻemi nui ʻo ARA-290 i ka cisplatin-induced cytotoxicity a me ka genotoxicity, e like me ka hoʻemi ʻana i nā ʻāpana hōʻino DNA i nā hōʻike comet a me ka micronucleus frequency, ka pale ʻana i nā mea genetic cellular a me ka hoʻēmi ʻana i ka pōʻino o ka renal cell [1].
Hoʻoponopono o ka Oxidative Stress and Inflammation: ARA-290 hoʻomaikaʻi i ka cisplatin-induced stress oxidative ma ka hoʻemi ʻana i ka malondialdehyde (MDA) a me nā pae ROS a me ka hoʻonui ʻana i ka hana enzyme antioxidant. Hoʻopau pū ia i ka ʻeha o ka renal ma ka hoʻemi ʻana i nā cytokine pro-inflammatory (e laʻa, TNF-α, IL-6, IL-1β), e pale ana i ka cisplatin-induced renal injury [1] .
Hoʻopaʻa i ka Apoptosis: ARA-290 ke kāohi i ka apoptosis i hoʻokomo ʻia i ka cisplatin ma ka hoʻoponopono ʻana i nā genes pili i ka apoptosis a me nā protein (e like me ka hoʻohaʻahaʻa ʻana i ka Caspase-3 a me ka ʻōlelo Bax, hoʻonui i ka hōʻike Bcl-2), mālama i ke ola ʻana o ka renal cell a me ka paʻa ʻana no ka mālama ʻana i nā maʻi maʻi hōʻeha ʻeha ..
Hoʻomaikaʻi i nā hōʻailona Depressive
ʻO ka hoʻohaʻahaʻa ʻana i ke ʻano o ke kaumaha e like me ke kaumaha: Ma nā ʻano ʻiole o ke koʻikoʻi haʻahaʻa hiki ʻole ke ʻike ʻia a me ke koʻikoʻi lanakila ʻana o ka nohona, ʻoi aku ka maikaʻi o ka hoʻokele ARA-290 i kēlā me kēia lā, i hoʻohālikelike ʻia me ka fluoxetine antidepressant maʻamau. Ua hoʻohana ʻo ARA-290 i nā hopena antidepressant me ka ʻole o ka hopena nui o ka hemoglobin peripheral a i ʻole nā ʻulaʻula ʻulaʻula [5].
Hoʻoponopono i nā Cells Immune and Inflammation: Hoʻololi ʻo ARA-290 i ka piʻi ʻana o ke kaumaha maʻamau i ka pinepine a me ka helu o CD11b⁺Ly6Ghi neutrophils a me CD11b⁺Ly6Chi monocytes i loko o ka iwi iwi a me nā meninges, a me ka microglial activation, e hoʻolaʻa ana i nā hopena anti-inflammatory hou no ka mālama ʻana i nā hopena depressive a me nā hōʻailona hou ..
Palekana no ka poino o ka ma'i diabetic
Kāohi i ka Renal Tubular Epithelial Apoptosis: ARA-290 inhibits renal tubular epithelial cell apoptosis, e hōʻemi ana i ka make cell programmed a me ka pale ʻana i nā cell renal.
ʻO ka hoʻomaikaʻi ʻana i nā hōʻailona hana Renal: ARA-290 e hoʻemi i ka helu urinary albumin excretion rate ma nā ʻiole maʻi maʻi, hoʻēmi i ka pōʻino pathological renal, hoʻomaikaʻi i ka hana renal, a hoʻopaneʻe i ka holomua nephropathy diabetic.
Lapaʻau ʻana o Systemic Lupus Erythematosus (SLE)
Hoʻopaʻa i ka Autoantibody Production a me ka Immune Complex Deposition: ARA-290 nui ke kāohi i ka serum antinuclear antibody (ANA) a me ka anti-double-stranded DNA antibody pae i nā ʻiole SLE i hoʻokomo ʻia, hoʻemi i ka waiho ʻana o IgG a me C3 i loko o nā puʻupaʻa, hoʻēmi i nā hōʻailona nephritis, a hoʻomaikaʻi i ka holomua o ka maʻi [6].
Hōʻike 1 ARA290 lapaʻau i hoʻopau i ka pane inflammatory i nā ʻiole SLE i hoʻokomo ʻia i pristane. (A) Ua ʻike ʻia nā pae o IL-6, IL-10, MCP-1, IFN-γ, TNF-α, IL-12p70 a me TGF-β i loko o ka serum ma hope o ka mālama ʻana i wehewehe ʻia ma ke Kiʻi 1 (n = 6). (B) ʻO ka inflammatory macrophage F4 / 80 infiltration ua kāohi nuiʻia e ka ARA 290 intervention i hoʻohālikelikeʻia me ka mana PBS. (C) Ua ana ʻia ke kaupaona ʻana o ka spleen a me ka lymph node ma hope o ka mālama ʻana o ARA290 i nā ʻiole SLE (n = 6). He 30 μm nā pā unahi.
Puna:PubMed [6]
Ka ho'ēmiʻana o nā kiʻekiʻe Cytokine Inflammatory: ARA-290 e ho'ēmi ana i ka nui o ka serum o nā cytokines inflammatory IL-6, MCP-1, a me TNF-α i nāʻiole SLE, e ho'ēmi ana i ka mumū a me ka hoʻohaʻahaʻaʻana i nā hōʻailona maʻi [6].
Hoʻemi ʻia ka Apoptosis: Hoʻemi ʻo ARA-290 i ka helu o nā cell apoptotic i loko o nā puʻupaʻa, pale i nā cell renal, a kāohi i ka hoʻoulu ʻana o nā macrophages i ka wā e hoʻolaha ana i kā lākou phagocytosis o nā cell apoptotic in vitro, e hoʻoponopono ana i ka ʻōnaehana immune a me ka paʻa ʻana i ka hiki no ka mālama SLE [6].
Hoʻemi i ka lāʻau lapaʻau Chemotherapeutic
Hoʻemi i ka pōʻino o ka DNA: Ma nā ʻano cytotoxicity i hoʻokomo ʻia e doxorubicin (DOX), ʻo ARA-290 ka mea e hōʻemi nui ai i ka pōʻino DNA i hoʻoiho ʻia e DOX, e like me ka emi ʻana o ka helu DNA o ka huelo ma nā hoʻokolohua comet a me ka micronucleus frequency, ka pale ʻana i nā mea genetic cellular a me ka hōʻemi ʻana i ka pōʻino chemotherapeutic i nā cell maʻamau [7].
Hoʻohaʻahaʻa i ka Oxidative Stress and Inflammation: ARA-290 e hoʻemi i ka DOX-induced impairment o ka hana antioxidant enzyme, e hoʻemi i ka mumū a me ka apoptosis, a pale aku i ka DOX-induced oxidative stress a me ka pōʻino cell, hiki ke komo pū me nā cell cardiac, e hoʻēmi i nā hopena ʻino i nā maʻi chemotherapy [7].
Kāohi a mālama ʻana i ka maʻi o Alzheimer
Hoʻonui i ka holomua o ka pathological a me ka hoʻomaikaʻi ʻana i ka cognition: ʻo ka hoʻokele mua ʻana o ARA-290 i nā ʻiole ʻōpio APP / PS1 (ke kumu hoʻohālike mua o Alzheimer) e hoʻolōʻihi i ka holomua pathological β-amyloid (Aβ) a hoʻomaikaʻi i ka hana cognitive, e hōʻike ana i kona koʻikoʻi no ka hana mua [8].
Hoʻoponopono i ka hana Monocyte: ARA-290 hoʻoulu kūikawā i ka hanauna o Ly6C⁻ patrolling monocyte subsets, hoʻonui i ko lākou pae holoʻokoʻa, hoʻoikaika i ka hoʻomaʻemaʻe Aβ mai nā kīʻaha koko cerebral, hoʻemi i ka kaumaha o ka lolo Aβ, a hoʻopaneʻe i ka piʻi ʻana o ka maʻi. Eia naʻe, ʻaʻole maikaʻi loa ia i nā hiʻohiʻona hope loa (aged APP/PS1 mice), e hōʻike ana i ke koʻikoʻi o ka hana mua [8].
Hoʻolaʻa ʻia ka hoʻōla ʻana i ka maʻi maʻi diabetes
Hoʻopili ʻia ka ʻeha ʻeha: Ma nā hiʻohiʻona ʻiole maʻi maʻi maʻi maʻi streptozotocin, ʻo ka noi ARA-290 kūloko e hoʻolalelale i ka pani ʻana i ka ʻeha, hoʻopōkole i ka manawa reepithelialization, a hoʻomaikaʻi i ka maikaʻi o ka hōʻeha ʻana [9] .
Hoʻoponopono i nā hōʻailona hoʻoponopono kino: ARA-290 hoʻonui i ka collagen a me ka protein i loko o nā ʻiʻo hoʻoponopono, hoʻoponopono i ka insulin serum, glucose koko, pae lipid, kūlana antioxidant, a me nā pae cytokine pro-inflammatory, e hana ana i kahi microenvironment kūpono i ka hōʻeha ʻana a me ka hāʻawi ʻana i nā hoʻolālā hou no ka mālama ʻana i nā maʻi maʻi maʻi maʻi ..
Hoʻomaha ʻeha
Hoʻopau i ka TRPV1 Channel Activity: Hoʻokuʻu ʻo ARA-290 i ka capsaicin-induced mechanical allodynia ma ke kāohi ʻana i ka transient receptor potential vanilloid subtype 1 (TRPV1) channel channel, e kuhikuhi pono ana i nā nociceptors peripheral a hāʻawi i nā pahuhopu therapeutic hou a me nā ala no ka mālama ʻana i ka ʻeha [4].
Ka hopena
ʻO ARA-290 kahi polypeptide i loaʻa i ka EPO me nā hopena anti-inflammatory, anti-apoptotic, a me nā hopena anti-oxidative. Hiki iā ia ke mālama i ka ʻeha i ka maʻi maʻi a me ka sarcoidosis, e hoʻoikaika i ka hoʻōla hou ʻana o ke aʻalolo, ka hakakā ʻana i ka nephrotoxicity, SLE, ke kaumaha, a me ka hoʻohaʻahaʻa ʻana i ka ʻeha ma o ka antagonizing TRPV1. Me ka hiki i ka hoʻomaka ʻana o Alzheimer a me nā kula ʻē aʻe, paʻa ia i nā manaʻo noiʻi lapaʻau ākea.
No ka mea kakau
ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.
Mea kākau moʻolelo ʻepekema
ʻO Al-Onaizi, he loea ʻo Mohammed me ka ʻike hohonu i ka ʻoihana biomedicine. Loaʻa iā ia nā pilina pili me kekahi mau keʻena hoʻonaʻauao a me nā noiʻi kaulana, me Dasman Diabetes Institute (DDI), Ke Kulanui ʻo Kuwait, ke Kulanui ʻo Laval, ke Kulanui o Western (University of Western Ontario), a me ke Kulanui Hebera o Ierusalema. He ākea kāna mau noiʻi noiʻi, e uhi ana i nā Neurosciences & Neurology, Biochemistry & Molecular Biology, Immunology, Psychiatry, a me nā kumuhana ʻē aʻe ma Life Science & Biomedicine. He mea koʻikoʻi kēia mau aʻo ʻana no ka loaʻa ʻana o ka ʻike hohonu o nā mīkini physiological kanaka, nā kaʻina maʻi, a me ka hoʻomohala ʻana i nā lāʻau lapaʻau hou. Al-Onaizi, Mohammed ka noiʻi ua loaʻa nā hopena koʻikoʻi ma ka ʻepekema kumu a ua hāʻawi i ke kākoʻo theoretical koʻikoʻi a me ke alakaʻi kūpono no ka lāʻau lapaʻau a me ka noiʻi biomedical.
